#AmazonPharmacy #GLP1 #Zepbound #HealthcareInvesting #PharmaStrategy #Amazon #Lilly #Fintech #Logistics #InvestorInsights #PricingPower To view or add a comment, sign in More Relevant Posts Access and affordability should work together
If a clinical trial shows that a new treatment is better than one currently being used, the new treatment may become "standard." Patients may want to think about taking part in a clinical trial
Twelve months after stopping a GLP-1, 33% of patients had further improved their HbA1c compared to when they discontinued the GLP-1, 46% kept some of their improvement, and 21% had a worse HbA1c compared to their pre-GLP-1 level
When Joe Rogan described BPC-157 as "Wolverine shit" on his podcast after experiencing rapid tendonitis recovery, the nickname stuck
In brief, dual GLP-1/GIP receptor agonist might be more protective in crucial biomarkers of neurodegeneration in brain than a GLP-1 based agonist